Brief: Omega Therapeutics Announces First Patient Dosed In Landmark Mychelangelo™ I Trial Of Otx-2002 In Hepatocellular Carcinoma And Other Solid Tumor Types Associated With The Myc Oncogene
27/10/2022 12:44
Oct 27 (Reuters) - Omega Therapeutics Inc OMGA.O :
* OMEGA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
LANDMARK
MYCHELANGELO™ I TRIAL OF OTX-2002 IN HEPATOCELLULAR CARCINOMA
AND OTHER SOLID TUMOR TYPES ASSOCIATED WITH THE MYC ONCOGENE
Source text for Eikon: ID:nPn1J9rvza
Further company coverage: OMGA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Omega Liquidating
See all newsBrief: Omega Therapeutics Files For Chapter 11 Bankruptcy In U.S. - Court Filing
Brief: Omega Therapeutics Announces Entry Into New Financing Facilities To Fund Sale Process And Wind Down Of Any Remaining Co Assets
Brief: Omega Therapeutics Receives Notice Of Default Under The Loan And Security Agreement Between Company And Banc Of California
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
Brief: Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence